Sivik Global Healthcare LLC held its position in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 10,000 shares of the life sciences company’s stock at the close of the second quarter. Sivik Global Healthcare LLC’s holdings in Illumina were worth $1,735,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of ILMN. HPM Partners LLC increased its holdings in Illumina by 29,103.8% during the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock valued at $107,724,000 after acquiring an additional 749,424 shares in the last quarter. TIAA CREF Investment Management LLC boosted its stake in shares of Illumina by 55.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock worth $256,058,000 after purchasing an additional 527,548 shares during the last quarter. American Century Companies Inc. boosted its stake in shares of Illumina by 276.9% during the 2nd quarter. American Century Companies Inc. now owns 475,111 shares of the life sciences company’s stock worth $82,441,000 after purchasing an additional 349,058 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Illumina by 3.0% during the 1st quarter. Vanguard Group Inc. now owns 9,648,842 shares of the life sciences company’s stock worth $1,646,479,000 after purchasing an additional 285,379 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its stake in shares of Illumina by 1,110.5% during the 1st quarter. Baird Financial Group Inc. now owns 279,120 shares of the life sciences company’s stock worth $47,629,000 after purchasing an additional 256,061 shares during the last quarter. Hedge funds and other institutional investors own 93.32% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/18/illumina-inc-ilmn-position-held-by-sivik-global-healthcare-llc.html.

In related news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $178.21, for a total value of $3,564,200.00. Following the completion of the sale, the director now owns 534,176 shares of the company’s stock, valued at approximately $95,195,504.96. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $174.24, for a total value of $25,264.80. Following the completion of the sale, the senior vice president now directly owns 10,646 shares of the company’s stock, valued at approximately $1,854,959.04. The disclosure for this sale can be found here. In the last three months, insiders sold 195,434 shares of company stock valued at $37,480,647. 1.60% of the stock is currently owned by company insiders.

Illumina, Inc. (NASDAQ ILMN) traded down 0.02% on Monday, reaching $210.67. 47,039 shares of the company traded hands. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $214.34. The stock has a market capitalization of $30.76 billion, a price-to-earnings ratio of 42.27 and a beta of 0.81. The firm has a 50 day moving average price of $197.88 and a 200 day moving average price of $180.42.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.14. The business had revenue of $662.00 million during the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.86 EPS. Equities research analysts predict that Illumina, Inc. will post $3.65 EPS for the current year.

Several research firms have issued reports on ILMN. Argus raised their price target on shares of Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a research note on Wednesday, September 13th. Leerink Swann reaffirmed an “outperform” rating and set a $225.00 price target (up from $207.00) on shares of Illumina in a research note on Tuesday, September 12th. Vetr cut shares of Illumina from a “buy” rating to a “hold” rating and set a $209.78 price target on the stock. in a research note on Thursday, August 31st. Zacks Investment Research cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Finally, Barclays PLC reaffirmed an “equal weight” rating and set a $150.00 price target on shares of Illumina in a research note on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $181.76.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.